HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate Stays Course On Earnings Forecast Against Stormy Headwinds From Costs

Executive Summary

Higher material and packaging costs in North America drove Colgate’s Q2 operating profit down 21%. Oral care sales were the bright spot in an otherwise difficult quarter in North America, where total sales declined 4% due to COVID-related demand in 2020 and competitive pressure.

You may also be interested in...



Colgate Expects ‘Volatile’ Short Term In Emerging Markets Before ‘Prosperity’ In Longer Term

“If you take a three- to five-year horizon, after a period of slowdown potentially, logically, we should expect another economic cycle that there will be more growth and prosperity," says Panagiotis Tsourapas, Colgate group president for Latin America, Asia-Pacific and Africa/Eurasia.

Colgate Battles Inflation And Costs Headwind With Price Hikes, Digital Marketing, Oral Care Focus

Colgate invests in oral care products, particularly in whitening segment, and digital marketing to counter inflation battering its bottom line, says president and CEO Noel Wallace. Overall pricing increased 3% from the second quarter.

Colgate Shifts Innovation Focus From Growing Sales In Core Segments To Expanding Categories

Colgate shifts innovation focus to product launches that expand categories and grow sales for the long term. “We have to expand the pie in the categories that we compete … we’re not going to do that with simply core adjacencies,” says CEO Noel Wallace.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151622

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel